-
Je něco špatně v tomto záznamu ?
Metabolic status of CSF distinguishes rats with tauopathy from controls
R. Karlíková, K. Mičová, L. Najdekr, A. Gardlo, T. Adam, P. Majerová, D. Friedecký, A. Kováč,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2009-06-01
BioMedCentral Open Access
od 2009
Directory of Open Access Journals
od 2009
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009 do 2020
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
Springer Nature OA/Free Journals
od 2009-06-01
- MeSH
- apoptóza genetika MeSH
- biologické markery metabolismus MeSH
- krysa rodu rattus MeSH
- lidé MeSH
- metabolomika MeSH
- modely nemocí na zvířatech MeSH
- mozek metabolismus patologie MeSH
- mutace genetika MeSH
- potkani inbrední SHR MeSH
- potkani transgenní MeSH
- proteiny tau genetika metabolismus MeSH
- tauopatie diagnóza genetika MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer's disease is the most prevalent tauopathy, affecting more than 35 million people worldwide. In this study we investigated changes in metabolic pathways associated with tau-induced neurodegeneration. METHODS: Cerebrospinal fluid (CSF), plasma and brain tissue were collected from a transgenic rat model for tauopathies and from age-matched control animals. The samples were analysed by targeted and untargeted metabolomic methods using high-performance liquid chromatography coupled to mass spectrometry. Unsupervised and supervised statistical analysis revealed biochemical changes associated with the tauopathy process. RESULTS: Energy deprivation and potentially neural apoptosis were reflected in increased purine nucleotide catabolism and decreased levels of citric acid cycle intermediates and glucose. However, in CSF, increased levels of citrate and aconitate that can be attributed to glial activation were observed. Other significant changes were found in arginine and phosphatidylcholine metabolism. CONCLUSIONS: Despite an enormous effort invested in development of biomarkers for tauopathies during the last 20 years, there is no clinically used biomarker or assay on the market. One of the most promising strategies is to create a panel of markers (e.g., small molecules, proteins) that will be continuously monitored and correlated with patients' clinical outcome. In this study, we identified several metabolic changes that are affected during the tauopathy process and may be considered as potential markers of tauopathies in humans.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024633
- 003
- CZ-PrNML
- 005
- 20180712091838.0
- 007
- ta
- 008
- 180709s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13195-017-0303-5 $2 doi
- 035 __
- $a (PubMed)28934963
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Karlíková, Radana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 245 10
- $a Metabolic status of CSF distinguishes rats with tauopathy from controls / $c R. Karlíková, K. Mičová, L. Najdekr, A. Gardlo, T. Adam, P. Majerová, D. Friedecký, A. Kováč,
- 520 9_
- $a BACKGROUND: Tauopathies represent heterogeneous groups of neurodegenerative diseases that are characterised by abnormal deposition of the microtubule-associated protein tau. Alzheimer's disease is the most prevalent tauopathy, affecting more than 35 million people worldwide. In this study we investigated changes in metabolic pathways associated with tau-induced neurodegeneration. METHODS: Cerebrospinal fluid (CSF), plasma and brain tissue were collected from a transgenic rat model for tauopathies and from age-matched control animals. The samples were analysed by targeted and untargeted metabolomic methods using high-performance liquid chromatography coupled to mass spectrometry. Unsupervised and supervised statistical analysis revealed biochemical changes associated with the tauopathy process. RESULTS: Energy deprivation and potentially neural apoptosis were reflected in increased purine nucleotide catabolism and decreased levels of citric acid cycle intermediates and glucose. However, in CSF, increased levels of citrate and aconitate that can be attributed to glial activation were observed. Other significant changes were found in arginine and phosphatidylcholine metabolism. CONCLUSIONS: Despite an enormous effort invested in development of biomarkers for tauopathies during the last 20 years, there is no clinically used biomarker or assay on the market. One of the most promising strategies is to create a panel of markers (e.g., small molecules, proteins) that will be continuously monitored and correlated with patients' clinical outcome. In this study, we identified several metabolic changes that are affected during the tauopathy process and may be considered as potential markers of tauopathies in humans.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a apoptóza $x genetika $7 D017209
- 650 _2
- $a biologické markery $x metabolismus $7 D015415
- 650 _2
- $a mozek $x metabolismus $x patologie $7 D001921
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolomika $7 D055432
- 650 _2
- $a mutace $x genetika $7 D009154
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani inbrední SHR $7 D011918
- 650 _2
- $a potkani transgenní $7 D055647
- 650 _2
- $a tauopatie $x mok mozkomíšní $x diagnóza $x genetika $7 D024801
- 650 _2
- $a proteiny tau $x genetika $x metabolismus $7 D016875
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Mičová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 700 1_
- $a Najdekr, Lukáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 700 1_
- $a Gardlo, Alžběta $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 700 1_
- $a Adam, Tomáš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 700 1_
- $a Majerová, Petra $u Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská cesta 9, 84510, Bratislava, Slovak Republic. AXON Neuroscience R&D, Dvořákovo nábrežie 10, 811 02, Bratislava, Slovak Republic.
- 700 1_
- $a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 5, 779 00, Olomouc, Czech Republic. Department of Clinical Biochemistry, University Hospital Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic. Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacký University Olomouc, I. P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 700 1_
- $a Kováč, Andrej $u Institute of Neuroimmunology, Slovak Academy of Sciences, Dúbravská cesta 9, 84510, Bratislava, Slovak Republic. andrej.kovac@savba.sk. AXON Neuroscience R&D, Dvořákovo nábrežie 10, 811 02, Bratislava, Slovak Republic. andrej.kovac@savba.sk.
- 773 0_
- $w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 9, č. 1 (2017), s. 78
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28934963 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712092131 $b ABA008
- 999 __
- $a ok $b bmc $g 1316764 $s 1021554
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 9 $c 1 $d 78 $e 20170921 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
- LZP __
- $a Pubmed-20180709